Amryt Pharma PLC – Trading Update

Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, today announces a trading update for...

Read More

Amryt Pharma plc Final Results

Revenues increased to €12.8m (2016: €1.4m) - driven by growth of Lojuxta drug sales. Cash balances totalled €20.5m at 31 December 2017 (2016: €8.3m), with €10m undrawn from the European...

Read More